Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Postvaccinal Immunity |
| Generic Name : | Haemagglutinin and Neuraminidase |
| Drug description : | Suspension for injection in prefilled syringes; a colourless clear liquid, filled in single-dose syringes (glass, type I). |
| Presentation : | Imuvac 2008/2009, suspension for injection (influenza vaccine, surface antigen, inactivated). Influenza virus surface antigens (haemagglutinin and neuraminidase)* of strains: - A/Brisbane/59/2007 (H1N1)-like strain - (A/Brisbane/59/2007 IVR-148 reass.) = 15 micrograms HA** - A/Brisbane/10/2007 (H3N2)-like strain - (A/Uruguay/716/2007 NYMC X-175C reass.) = 15 micrograms HA** - B/Florida/4/2006-like strain - (B/Florida/4/2006) = 15 micrograms HA** per 0.5 ml dose. * propagated in hen's eggs. ** haemagglutinin. This vaccine complies with the WHO recommendation (northern hemisphere), and the decision of the EU for the 2008/2009 season |
| Indications : | Prophylaxis of influenza, especially in those who run an increased risk of associated complications. The use of Imuvac 2008/2009 should be based on official recommendations. |
| Adult Dosage : | Adults and children from 36 months: 0.5 ml. Children from 6 months to 35 months: Clinical data are limited. Dosages of 0.25 ml or 0.5 ml have been used. For children who have not previously been vaccinated, a second dose should be given after an interval of at least 4 weeks. Immunisation should be carried out by intramuscular or deep subcutaneous injection. |
| Contra Indications : | Hypersensitivity to the active substances, to any of the excipients and to eggs, chicken protein (Imuvac 2008/2009 does not contain more than 1 µg ovalbumin per dose), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, or gentamicin. Immunisation shall be postponed in patients with febrile illness or acute infection. |
| Special Precautions : | As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine. Imuvac 2008/2009 should under no circumstances be administered intravascularly. Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient. |
| Interactions : | Imuvac 2008/2009 may be given at the same time as other vaccines. Immunisation should be carried out on separate limbs. It should be noted that the adverse reactions may be intensified. The immunological response may be diminished if the patient is undergoing immunosuppressant treatment. Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been observed. The Western Blot technique disproves the false-positive ELISA test results. The transient false-positive reactions could be due to the IgM response by the vaccine. Pregnancy and lactation The limited data from vaccinations in pregnant women do not indicate that adverse fetal and maternal outcomes were attributable to the vaccine. The use of this vaccine may be considered from the second trimester of pregnancy. For pregnant women with medical conditions that increase their risk of complications from influenza, administration of the vaccine is recommended, irrespective of their stage of pregnancy. Imuvac 2008/2009 may be used during lactation. |
| Adverse Reactions : | The safety of trivalent inactivated influenza vaccines is assessed in open label, uncontrolled clinical trials performed as annual update requirement, including at least 50 adults aged 18 - 60 years of age and at least 50 elderly aged 61 years or older. Safety evaluation is performed during the first 3 days following vaccination. The following undesirable effects have been observed during clinical trials with the following frequencies: Nervous system disorders: Headache* Skin and subcutaneous tissue disorders: Sweating* Musculoskeletal and connective tissue disorders: Myalgia, arthralgia* General disorders and administration site conditions: fever, malaise, shivering, fatigue Local reactions: redness, swelling, pain, ecchymosis induration* * these reactions usually disappear within 1-2 days without treatment ADVERSE REACTIONS REPORTED FROM POST-MARKETING SURVEILLANCE Adverse reactions reported from post marketing surveillance are, next to the reactions which have also been observed during the clinical trials, the following: Blood and lymphatic system disorders: Transient thrombocytopenia, transient lymphadenopathy Immune system disorders: Allergic reactions, in rare cases leading to shock, angioedema Nervous system disorders: Neuralgia, paraesthesia, febril convulsions, neurological disorders, such as encephalomyelitis, neuritis and Guillain Barré syndrome Vascular disorders: Vasculitis associated in very rare cases with transient renal involvement Skin and subcutaneous tissue disorders: Generalised skin reactions including pruritus, urticaria or non-specific rash |
| Manufacturer : | Solvay Healthcare |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org